Enhanced adherence of human uremic erythrocytes to vascular endothelium: Role of phosphatidylserine exposure

Kidney International

Volumn 62, Issue 4, 2002, Pages 1358-1363

  Bonomini, Mario ^a   Sirolli, Vittorio ^a   Gizzi, Federico ^a   Di Stante, Silvio ^a   Grilli, Alfredo ^a   Felaco, Mario ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Apoptosis; Chronic renal failure; Coagulation; Endothelial cells; Thrombospondin; Uremia; Vascular injury

Indexed keywords

LIPOCORTIN 5; LIPOSOME; MONOCLONAL ANTIBODY; PHOSPHATIDYLSERINE; THROMBOSPONDIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL INJURY; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE ADHESIVENESS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MALE; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; ULTRASTRUCTURE; UMBILICAL VEIN; UREMIA; VASCULAR ENDOTHELIUM;

EID: 0036380903     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00560.x     Document Type: Article

References (40)

1. BRETSCHER MS: Asymmetric lipid bilayer structure for biological membranes. Nature 236:11-12, 1972
2. DEVAUX PF, ZACHOWSKI A: Maintenance and consequences of membrane phospholipid asymmetry. Chem Phys Lipids 73:107-120, 1994
3. ZWAAL RFA, SCHROIT AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89:1121-1132, 1997
4. VAN ENGELAND M, KUIJPERS HJH, RONSEVERS FCS, et al: Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 235:421-430, 1997
5. SCHLEGEL RA, PRENDERGAST TW, WILLIAMSON P: Membrane phospholipid asymmetry as a factor in erythrocyte-endothelial cell interactions. J Cell Physiol 123:215-218, 1985
6. WALI RK, JAFFE S, KUMAR VK, KALRA VK: Alterations in organization of phospholipids in erythrocytes as factor in adherence to endothelial cells in diabetes mellitus. Diabetes 37:104-111, 1988
7. CLOSSE C, DACHARY-PRIGENT J, BOISSEAU MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haemat 107:300-302, 1999
8. MANODORI AB, BARABINO GA, LUBIN BH, KUYPERS FA: Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. Blood 95:1293-1300, 2000
9. KALRA VK, BANERJEE R, SORGENTE N: Heterotypic and homotypic cell-cell adhesion molecules in endothelial cells. Biotechnol Appl Biochem 12:579-585, 1990
10. INAUEN W, STAUBLLI M, DESCOEUDRE C, et al: Erythrocyte deformability in dialysed and non-dialysed uraemic patients. Eur J Clin Invest 12:173-176, 1982
11. KELLY RA, CANESSA ML, STEINMAN TI, MITCH WE: Hemodialysis and red cell cation transport in uremia: Role of membrane free fatty acids. Kidney Int 35:595-603, 1989
12. LINDNER A, GAGNE E-R, ZINGRAFF J, et al: A circulating inhibitor of the RBC membrane calcium pump in chronic renal failure. Kidney Int 42:1328-1335, 1992
13. PERNA AF, INGROSSO D, ZAPPIA V, et al: Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. J Clin Invest 91:2497-2503, 1993
14. BONOMINI M, SIROLLI V, SETTEFRATI N, et al: Increased erythrocyte phosphatidylserine exposure in chronic renal failure. J Am Soc Nephrol 10:1982-1990, 1999
15. BONOMINI M, SIROLLI V, REALE M, ARDUINI A: Involvement of phosphatidylserine exposure in the recognition and phagocytosis of uremic erythrocytes. Am J Kidney Dis 37:807-814, 2001
16. KAYE M: The anemia associated with renal disease. J Lab Clin Med 52:83-100, 1958
17. WILSON MJ, RICHTER-LOWNEY K, DALEKE DL: Hyperglycemia induces a loss of phospholipid asymmetry in human erythrocytes. Biochemistry 32:11302-11310, 1993
18. FADOK VA, VOELKER DR, CAMPBELL PA, et al: Exposure of phasphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207-2216, 1992
19. MANODORI AB, MATSUI NM, CHEN JY, EMBURY SH: Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation. Blood 92:3445-3454, 1998
20. PRATER CA, PLOTKIN J, JAYE D, FRAZIER WA: The properdin-like type I repeats of human thrombospondin contain a cell attachment site. J Cell Biol 112:1031-1040, 1991
21. KUYPERS FA, YUAN J, LEWIS RA, et al: Membrane phospholipid asymmetry in human thalassemia. Blood 91:3044-3051, 1998
22. WOOD BL, GIBSON DF, TAIT JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical associations. Blood 88:1873-1880, 1996
23. BORNSTEIN P: Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 130:503-506, 1995
24. ASCH AS, TEPLER J, SILBIGER S, NACHMAN RL: Cellular attachment to thrombospondin. Cooperative interaction between receptor systems. J Biol Chem 266:1740-1745, 1991
25. ADAMS JC, LAWLER J: Diverse mechanisms for cell attachment to platelet thrombospondin. J Cell Sci 104:1061-1076, 1993
26. ASCH AS, NACHMAN RL: Thrombospondin: Phenomenology to function. Prog Hemost Thromb 89:157-176, 1989
27. MOSHER DF, DOYLE MJ, JAFFE EA: Synthesis and secretion of thrombospondin by cultured human endothelial cells. J Cell Biol 93:343-348, 1982
28. REINDERS JH, DEGROOT PG, DAWES J, et al: Comparison of secretion and subcellular localization of von Willebrand protein with that of thrombospondin and fibronectin in cultured human vascular endothelial cells. Biochim Biophys Acta 844:306-313, 1985
29. LAWLER J, HYNES RO: The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 103:1635-1648, 1986
30. HEBBEL RP, MOHANDAS N: Sickle cell adherence, in Sickle Cell Disease: Basic Principles and Clinical Practice, edited by EMBYRY SH, HEBBEL RP, MOHANDAS N, STEINBERG MH, New York, Raven Press Ltd, 1994, pp 217-230
31. MOSSERI M, BARTLETT-PANDITE AN, WONC K, et al: Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J 126:338-346, 1993
32. EVANS HG, RYLEY HC, HELLET J, LEWIS MJ: Human red blood cells inhibit endothelium-derived relaxing factor (EDRF) activity. Eur J Pharmacol 163:361-364, 1989
33. MORRIS ST, JARDINE AG: The vascular endothelium in chronic renal failure. J Nephrol 13:96-105, 2000
34. NAKAYAMA M, YAMADA K, YAMAMOTO Y, et al: Vascular endothelial dysfunction in patients on regular dialysis treatment. Clin Nephrol 42: 117-120, 1994
35. GRIS J-C, BRANGER B, VELINA F, et al: Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 46:807-813, 1994
36. KARI JA, DONALD AE, VALLANCE DT, et al: Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 52:468-472, 1997
37. BONOMINI M, REALE M, SANTARELLI P, et al: Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 79:399-407, 1998
38. NORIS M, REMUZZI G: Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Phys 111:602-610, 1999
39. VALLANCE P, LEONE A, CALVER A, et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575, 1992
40. BLUM M, YACHNIN T, WOLLMAN Y, et al: Low nitric oxide production in patients with chronic renal failure. Nephron 79:265-268, 1998